Incyte (INCY) Competitors $83.63 -2.54 (-2.95%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, REGN, ALNY, BIIB, NBIX, UTHR, BMRN, EXEL, MDGL, and EXASShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), and Exact Sciences (EXAS). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Neurocrine Biosciences United Therapeutics BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Do analysts prefer ABBV or INCY? AbbVie presently has a consensus target price of $217.10, indicating a potential downside of 0.79%. Incyte has a consensus target price of $82.53, indicating a potential downside of 1.94%. Given AbbVie's stronger consensus rating and higher possible upside, research analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 4 Strong Buy rating(s) 2.92Incyte 1 Sell rating(s) 10 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger valuation & earnings, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$58.33B6.63$4.28B$2.10104.20Incyte$4.24B3.88$32.62M$4.4019.13 Which has more volatility & risk, ABBV or INCY? AbbVie has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Is ABBV or INCY more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Incyte 18.99%21.99%14.43% Does the media favor ABBV or INCY? In the previous week, AbbVie had 78 more articles in the media than Incyte. MarketBeat recorded 98 mentions for AbbVie and 20 mentions for Incyte. Incyte's average media sentiment score of 1.50 beat AbbVie's score of 1.12 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 69 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive Incyte 15 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ABBV or INCY? 70.2% of AbbVie shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAbbVie beats Incyte on 10 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.44B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio19.1321.4874.7325.99Price / Sales3.88301.34470.3491.76Price / Cash155.8045.3337.0859.91Price / Book4.709.6312.256.31Net Income$32.62M-$53.32M$3.28B$270.66M7 Day Performance-2.85%0.95%1.39%3.52%1 Month Performance3.14%9.68%7.70%6.79%1 Year Performance32.84%13.38%64.01%28.29% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7681 of 5 stars$83.63-2.9%$82.53-1.3%+36.5%$16.33B$4.24B19.012,617Positive NewsShort Interest ↓ABBVAbbVie4.794 of 5 stars$210.25+1.1%$214.95+2.2%+13.1%$371.68B$56.33B100.1255,000Trending NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.7814 of 5 stars$580.70+0.2%$817.67+40.8%-50.2%$61.55B$14.20B14.6315,106Positive NewsShort Interest ↑ALNYAlnylam Pharmaceuticals3.7289 of 5 stars$446.51-1.3%$405.33-9.2%+78.9%$58.53B$2.25B-180.772,230Positive NewsAnalyst ForecastInsider TradeBIIBBiogen4.6532 of 5 stars$132.22-0.3%$185.74+40.5%-25.2%$19.39B$9.68B12.647,605Positive NewsNBIXNeurocrine Biosciences4.7318 of 5 stars$139.60+0.5%$159.50+14.3%+18.2%$13.85B$2.36B41.301,800Positive NewsUTHRUnited Therapeutics4.8067 of 5 stars$304.76-0.8%$382.00+25.3%+16.9%$13.75B$2.88B11.901,305News CoveragePositive NewsAnalyst ForecastInsider TradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9525 of 5 stars$58.27+1.0%$93.17+59.9%-34.1%$11.19B$2.85B17.293,040Short Interest ↑EXELExelixis4.7283 of 5 stars$37.42-1.3%$44.06+17.7%+46.7%$10.07B$2.17B17.991,147Positive NewsMDGLMadrigal Pharmaceuticals4.3064 of 5 stars$437.85+0.2%$459.25+4.9%+88.6%$9.72B$180.13M-34.0790Positive NewsAnalyst ForecastInsider TradeEXASExact Sciences4.7995 of 5 stars$47.42+1.0%$67.05+41.4%-12.7%$8.98B$2.76B-8.737,000Positive NewsAnalyst ForecastShort Interest ↓Analyst Revision Related Companies and Tools Related Companies AbbVie Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Neurocrine Biosciences Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Madrigal Pharmaceuticals Competitors Exact Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts